The Feasibility of Using Coxiella burnetii Avirulent Nine Mile Phase II Viable Bacteria as a Live Attenuated Vaccine Against Q fever
Authors:
- Venkatesh KumaresanVKVenkatesh Kumaresan
- Shawkat AlamSAShawkat Alam
- Yan ZhangYZYan Zhang
- Guoquan ZhangGZGuoquan Zhang
Open Access
- 21 October 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12
Abstract
This study aimed to explore if viable C. burnetii avirulent Nine Mile phase II (NMII) can elicit protective immunity against virulent NM phase I (NMI) infection. Interestingly, mice immunized with viable NMII elicited significant protection against NMI infection at different time points post-immunization. Viable NMII induced a dose-dependent NMI-specific IgG response in mice, but all doses of NMII-immunized mice conferred a similar level of protection. Comparing different routes of immunization indicated that intranasally immunized mice showed significantly higher levels of protection than other immunization routes. The observation that viable NMII induced a similar level of long-term protection against NMI challenge as the formalin-inactivated NMI vaccine (PIV) suggests that viable NMII bacteria can induce a similar level of long-term protection against virulent NMI challenge as the PIV. Viable NMII also induced significant protection against challenge with virulent Priscilla and Scurry strains, suggesting that viable NMII can elicit broad protection. Immune sera and splenocytes from viable NMII-immunized mice are protective against NMI infection, but immune serum-receiving mice did not control NMI replication. Additionally, viable NMII conferred a comparable level of protection in wild-type, CD4+ T cell-deficient, and CD8+ T cell-deficient mice, and partial protection in B cell-deficient mice. However, NMII-immunized T cell-deficient mice were unable to prevent C. burnetii replication. Thus, both B cells and T cells are required for viable NMII-induced protective immunity but T cells may play a critical role. Collectively, this study demonstrates the feasibility of using avirulent NMII as a live attenuated vaccine against human Q fever.Keywords
This publication has 40 references indexed in Scilit:
- T‐cell‐inducing vaccines – what’s the futureImmunology, 2011
- Coxiella burnetii Phase I and II Variants Replicate with Similar Kinetics in Degradative Phagolysosome-Like Compartments of Human MacrophagesInfection and Immunity, 2010
- Laboratory Maintenance of Coxiella burnetiiCurrent Protocols in Microbiology, 2009
- T Cells Are Essential for Bacterial Clearance, and Gamma Interferon, Tumor Necrosis Factor Alpha, and B Cells Are Crucial for Disease Development inCoxiella burnetiiInfection in MiceInfection and Immunity, 2007
- Lounging in a lysosome: the intracellular lifestyle of Coxiella burnetiiCellular Microbiology, 2007
- Genetic Diversity of the Q Fever Agent,Coxiella burnetii, Assessed by Microarray-Based Whole-Genome ComparisonsJournal of Bacteriology, 2006
- The Role of Lipopolysaccharides in the Virulence of Coxiella burnetiiAnnals of the New York Academy of Sciences, 1990
- Vaccine prophylaxis of abattoir-associated Q fever: eight years' experience in Australian abattoirsEpidemiology and Infection, 1990
- Markers of Cell-Mediated Immunity After Vaccination with an Inactivated, Whole-Cell Q Fever VaccineThe Journal of Infectious Diseases, 1988
- Overlapping Deletion in Two Spontaneous Phase Variants of Coxiella burnetiiMicrobiology, 1986